Acta Scientific Women's Health (ASWH)(ISSN: 2582-3205)

Mini Review Volume 2 Issue 5

Currently Used Drugs for Prevention and Treatment of Acute Organ Rejection

Vera Maravić-Stojković* and Branislav Stojković

Dedinje Cardiovascular Institute, Belgrade, Serbia

*Corresponding Author: Vera Maravić-Stojković, Dedinje Cardiovascular Institute, Belgrade, Serbia

Received: January 30, 2020; Published: April 29, 2020



  It is clear from the knowledge gained from the ancient times that healing is not as simple process as it seems. During long periods of time, major advancements in technology, pharmacology, and medicine have enabled the extraction of countless remedial products from the plants. And not only from plants. Natural products have also been extracted from animal organs and later, synthetic equivalents with identical properties have been developed. The fascinating progress of humankind was achieved when the animal organs have become available as a drug. Nevertheless, revolutionary progress in solid organ transplantation was marked by the introduction of the cyclosporine A. Transplant immunology has become a leading science in modern medicine. Since then, solid organ transplantation has become a routine procedure accomplished with the help of protocols of immunosuppressive therapy. This article is designed as an overview of currently used immunosuppression in solid organ transplantation. Currently available groups: steroids, antimetabolites, polyclonal and monoclonal antibodies, calcineurin inhibitors, proliferation signal inhibitors, are described closely below. Each transplant center creates their own protocols. Protocols for immunosuppressive therapy offer three major strategies: induction, maintenance and therapy for treating acute rejection. The backbone of immunosuppression in organ transplantation recipient: cyclosporine A and tacrolimus, have been widely used as maintenance therapy combined with adjunctive immunosuppressant. These drugs are in use either as a prophylaxis or as the part of the maintenance immunosuppressive treatment. Induction therapy provides immunologic ablation with upstream antibody therapy as prelude to induce graft tolerance. Protocols are briefly described in the text.

Keywords: Immunosuppressive Agents; Solid Organ Transplantation



  1. Virgil Aeneid. 4.1-299: Latin Text, Study Questions, Commentary and Interpretative Essays (main text in Latin; commentary in English; Cambridge, UK: Open Book Publishers, 2012), by Virgil, ed. by Ingo Gildenhard (2012).
  2. Yale E. “First Blood Transfusion: A History”. JSTOR (2015).
  3. Borel JF., et al. “Biological effects of cyclosporin A: a new antilymphocytic agent”. Agents Actions4 (1976): 468-475.
  4. Calne R Y. “Organ transplantation: From laboratory to clinic”. British Medical Journal6511 (1985): 1751-1754.
  5. Maravić-Stojković V., et al. “Modern immunosuppressive agents after heart transplantation”. Current Trends in Cardiology 2 (2007): 31-41.
  6. Maravić-Stojković V. “The principles of modern immunosuppressive therapy after solid organ transplantation”. SJAIT 3-4 (2011): 255-259.
  7. Vincenti F., et al. “Beltacept Induction Prior to Cardiac Transplantation with Lower Intensity Maintenancand Long-therm outcomes in kidney transplantation”. NEJM4 (2016): 333-343.
  8. This study is currently recruiting participants. Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation.
  9. Matskeplishvili S. “Vladimir Petrovich Demikhov (1916–1998)”. European Heart Journal46 (2017): 3406-3410.
  10. Konstantinov IE. “A Mystery of Vladimir P. Demikhov: The 50th Anniversary of the First Intrathoracic Transplantation”. The Annals Thoracic Surgery (1998): 1171-1177.
  11. Gkasdaris G and Birbilis T. “First Human Head Transplantation: Surgically Challenging, Ethically Controversial and Historically Tempting – an Experimental Endeavor or a Scientific Landmark?” Maedica (Buchar) 14.1 (2019): 5-11.


Citation: Vera Maravić-Stojković and Branislav Stojković. “Currently Used Drugs for Prevention and Treatment of Acute Organ Rejection". Acta Scientific Women's Health 2.5 (2020): 15-19.


Acceptance rate35%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US